Defense World
18 Apr 2026, 05:05 UTC · 29w ago
Verdict
Headline takes no side. We score DMAC +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Phase II preeclampsia data showed DM199 produced a 25 mmHg drop in systolic pressure and a 13% reduction in uterine artery resistance index, while confirming the drug does not cross the placental barrier.
More positive than 99% of claims this week
DiaMedica plans to initiate a Phase II trial in the coming months and expects multiple clinical readouts over the coming year to select a Phase III dose for a roughly 250-patient pivotal study.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 98% of claims this week
In the acute ischemic stroke program, patients who received mechanical thrombectomy did not show a benefit from DM199, though an improvement was observed when those patients were excluded.
More negative than 92% of claims this week
Existing KLK1 therapies have established clinical use in Asia, with a human urinary-derived product treating almost 1 million patients annually for acute ischemic stroke.
More positive than 77% of claims this week
DM199 targets a potential 24-hour treatment window for acute ischemic stroke, vastly exceeding the 4.5-hour window of tPA and potentially expanding the treatable patient population.
More positive than 70% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company presented encouraging proof-of-concept data, a clean safety profile regarding the placental barrier, and outlined a clear path toward Phase II and III trials.
Near neutral — 90% of ticker scores this week are stronger
Mentioned as a distributor of a similar protein product in China, but the article does not provide news affecting its specific valuation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
15h ago
+32.0%
Price agrees with the score
$9.04 vs $6.85 close before publication (Apr 17) · not market-adjusted
DMAC chart →
